cmbg_nt10k.htm
 
       OMB APPROVAL
       OMB Number: 3235-0058
   UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
  Expires: August 31, 2015
 Estimated average burden
       hours per response.......2.50
       
  FORM 12b-25  SEC FILE NUMBER
   000-52282
       
       CUSIP NUMBER
   NOTIFICATION OF LATE FILING
276050101
 
 
 
 
(Check one): þ  Form 10-K o  Form 20-F o  Form 11-K o  Form 10-Q o  Form 10-D o  Form N-SAR o  Form N-CSR
                                                                                                                                                                                                                                                                                              
                             
      For Period Ended:   December 31, 2012
       
         
   o  Transition Report on Form 10-K
         
   o  Transition Report on Form 20-F
         
   o  Transition Report on Form 11-K
         
   o  Transition Report on Form 10-Q
         
   o  Transition Report on Form N-SAR
         
      For the Transition Period Ended:
                      
 
 
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
 
 
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
 
 
PART I — REGISTRANT INFORMATION

Cellular Biomedicine Group, Inc.
  
Full Name of Registrant
 
EastBridge Investment Group Corporation
  
Former Name if Applicable
 
530 University Avenue, #17  
Address of Principal Executive Office (Street and Number)
 
Palo Alto, California 94301  
City, State and Zip Code
 
 
 
 
 
 
PART II — RULES 12b-25(b) AND (c)
 
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25 (b), the following should be completed. (Check box if appropriate)
 
 
   (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
     
þ  (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D,or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
     
   (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
     
 
PART III – NARRATIVE
 
State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.
 
(Attach extra Sheets if Needed)
 
The Registrant has experienced a delay in completing the information necessary for inclusion in its Annual Report on Form 10-K for the year ended December 31, 2012 (the “Annual Report”). The registrant expects to file the Annual Report within the allotted extension period.
 
 
PART IV — OTHER INFORMATION

(1)
Name and telephone number of person to contact in regard to this notification
 
  Andrew Chan    (650)   566-5064 
 
(Name)
  
(Area Code)
  
(Telephone Number)
 
(2)
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
Yes 
 þ
No 
 o  
   
 
(3)
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
Yes 
 þ
No 
 o  
 
Fiscal Year Ended December 31, 2012, Compared to Fiscal Year Ended December 31, 2011
 
Revenues
 
Year Ended December 31,
  
Revenues
    
Change from Prior Year
    
Percent Change from Prior Year
  
                   
2012
   $ 9,368,771     $ 9,333,271       26291 %
2011
   $ 35,500                  
 
Revenues in fiscal 2012 increased by approximately $9,333,000, due primarily to timing of specific listing agreements with our clients which triggered payment obligations from our clients to us.  Most of the current agreements with EastBridge Sub stipulate that the receipt of revenue from them is dependent upon the successful listing of the client company on a U.S. stock exchange or other market.  The Company recognized revenue in 2012 based on receipt of shares in clients that were successfully listed.  For example, the Company met all of the milestones in the listing agreement with Wonder International in 2012.  In 2011, revenue was associated with cash fees for which services were fully rendered.
 
 
2
 
 
 
Cellular Biomedicine Group, Inc.
 
(Name of Registrant as Specified in Charter)
 
has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date:  April 2, 2013
    
By:
/s/ Andrew Chan
       
Andrew Chan, CFO
         

 
3